Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
Tigermed Reports 2024 Interim Results 2024-08-28 18:26
Fosun Pharma Announces 2024 Interim Results 2024-08-28 18:10
Harbour BioMed Announces 2024 Interim Results 2024-08-28 17:44
Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization 2024-08-28 17:29
Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist 2024-08-28 10:43
GenScript Subsidiary Legend Biotech Achieves Breakthrough with Cilta-cel Approval in China, Offering New Hope for Multiple Myeloma Patients 2024-08-27 22:28
Keymed Biosciences Announces Interim Results for First Half of 2024 2024-08-27 21:10
111, Inc. to Participate in Fireside Chat with Water Tower Research on September 5, 2024 2024-08-27 20:00
Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor 2024-08-26 22:00
Actinogen announces further positive results on depression in the XanCIDD phase 2a trial 2024-08-26 20:30
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference 2024-08-26 19:00
Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer 2024-08-23 22:00
CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer 2024-08-23 20:00
GenFleet Announces the First Approval of a KRAS G12C Inhibitor in China for Treatment of Advanced Non-small Cell Lung Cancer Patients Harboring KRAS G12C Mutation 2024-08-23 19:30
Corina Intrauterine Drug-Eluting System approved in China as a novel treatment for patients with moderate-to-severe intrauterine adhesions (IUA) 2024-08-23 18:45
Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program 2024-08-22 21:30
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA 2024-08-22 21:04
Stem Cell Therapy developers I Peace and iCamuno Biotherapeutics Start Natural Killer Cell Trial for Ovarian Cancer 2024-08-22 21:00
Ractigen Therapeutics Announces U.S. FDA Orphan Drug Designation (ODD) granted to RAG-18 for the treatment of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy 2024-08-22 20:00
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1 2024-08-22 18:00
1 8 9 10 11 12 165